Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

GlaxoSmithKline and CureVac are to begin developing a next generation vaccine targeting emerging variants of the coronavirus – although it is unlikely to be ready until at least next year.

Overview: CureVac N.V. is a biopharmaceutical company specializing in the development of transformative mRNA-based medicines, with a market cap of approximately $684.16 million. Operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...